Stryker Operating Income Growth & History (SYK)
Stryker's operating income was $4.89B for fiscal 2025.
View full Stryker company overviewStryker annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.89B | $1.20B | +32.53% |
| 2024 | 2024-12-31 | $3.69B | −$199.0M | −5.12% |
| 2023 | 2023-12-31 | $3.89B | $1.05B | +36.85% |
| 2022 | 2022-12-31 | $2.84B | $257.0M | +9.95% |
| 2021 | 2021-12-31 | $2.58B | $361.0M | +16.24% |
| 2020 | 2020-12-31 | $2.22B | −$490.0M | −18.06% |
| 2019 | 2019-12-31 | $2.71B | $176.0M | +6.94% |
| 2018 | 2018-12-31 | $2.54B | $240.0M | +10.45% |
| 2017 | 2017-12-31 | $2.30B | $122.0M | +5.61% |
| 2016 | 2016-12-31 | $2.17B | $314.0M | +16.87% |
| 2015 | 2015-12-31 | $1.86B | $615.0M | +49.36% |
| 2014 | 2014-12-31 | $1.25B | −$10.0M | −0.80% |
| 2013 | 2013-12-31 | $1.26B | −$485.0M | −27.86% |
| 2012 | 2012-12-31 | $1.74B | $55.0M | +3.26% |
| 2011 | 2011-12-31 | $1.69B | −$65.0M | −3.71% |
| 2010 | 2010-12-31 | $1.75B | $157.0M | +9.85% |
| 2009 | 2009-12-31 | $1.59B | $75.0M | +4.94% |
| 2008 | 2008-12-31 | $1.52B | $211.7M | +16.19% |
| 2007 | 2007-12-31 | $1.31B | — | — |
Stryker quarterly operating income
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.66B | $546.0M | +49.06% |
| Q1 2026 | 2026-03-31 | $936.0M | $99.0M | +11.83% |
| Q4 2025 | 2025-12-31 | $1.80B | $1.22B | +210.50% |
| Q3 2025 | 2025-09-30 | $1.14B | $50.0M | +4.61% |
| Q2 2025 | 2025-06-30 | $1.11B | $62.0M | +5.90% |
| Q1 2025 | 2025-03-31 | $837.0M | −$135.0M | −13.89% |
| Q4 2024 | 2024-12-31 | $581.0M | −$676.0M | −53.78% |
| Q3 2024 | 2024-09-30 | $1.08B | $154.0M | +16.54% |
| Q2 2024 | 2024-06-30 | $1.05B | $86.0M | +8.91% |
| Q1 2024 | 2024-03-31 | $972.0M | $237.0M | +32.24% |
| Q4 2023 | 2023-12-31 | $1.26B | $443.0M | +54.42% |
| Q3 2023 | 2023-09-30 | $931.0M | $123.0M | +15.22% |
| Q2 2023 | 2023-06-30 | $965.0M | $193.0M | +25.00% |
| Q1 2023 | 2023-03-31 | $735.0M | $288.0M | +64.43% |
| Q4 2022 | 2022-12-31 | $814.0M | −$5.0M | −0.61% |
| Q3 2022 | 2022-09-30 | $808.0M | $234.0M | +40.77% |
| Q2 2022 | 2022-06-30 | $772.0M | $40.0M | +5.46% |
| Q1 2022 | 2022-03-31 | $447.0M | −$12.0M | −2.61% |
| Q4 2021 | 2021-12-31 | $819.0M | $70.0M | +9.35% |
| Q3 2021 | 2021-09-30 | $574.0M | −$285.0M | −33.18% |
| Q2 2021 | 2021-06-30 | $732.0M | $752.0M | — |
| Q1 2021 | 2021-03-31 | $459.0M | −$176.0M | −27.72% |
| Q4 2020 | 2020-12-31 | $749.0M | −$195.0M | −20.66% |
| Q3 2020 | 2020-09-30 | $859.0M | $231.0M | +36.78% |
| Q2 2020 | 2020-06-30 | −$20.0M | −$633.0M | — |
| Q1 2020 | 2020-03-31 | $635.0M | $107.0M | +20.27% |
| Q4 2019 | 2019-12-31 | $944.0M | $246.0M | +35.24% |
| Q3 2019 | 2019-09-30 | $628.0M | $52.0M | +9.03% |
| Q2 2019 | 2019-06-30 | $613.0M | −$59.0M | −8.78% |
| Q1 2019 | 2019-03-31 | $528.0M | −$63.0M | −10.66% |
| Q4 2018 | 2018-12-31 | $698.0M | −$16.0M | −2.24% |
| Q3 2018 | 2018-09-30 | $576.0M | $51.0M | +9.71% |
| Q2 2018 | 2018-06-30 | $672.0M | $170.0M | +33.86% |
| Q1 2018 | 2018-03-31 | $591.0M | $35.0M | +6.29% |
| Q4 2017 | 2017-12-31 | $714.0M | $44.0M | +6.57% |
| Q3 2017 | 2017-09-30 | $525.0M | $39.0M | +8.02% |
| Q2 2017 | 2017-06-30 | $502.0M | $2.0M | +0.40% |
| Q1 2017 | 2017-03-31 | $556.0M | $37.0M | +7.13% |
| Q4 2016 | 2016-12-31 | $670.0M | $22.0M | +3.40% |
| Q3 2016 | 2016-09-30 | $486.0M | $108.0M | +28.57% |
| Q2 2016 | 2016-06-30 | $500.0M | $71.0M | +16.55% |
| Q1 2016 | 2016-03-31 | $519.0M | $113.0M | +27.83% |
| Q4 2015 | 2015-12-31 | $648.0M | $180.0M | +38.46% |
| Q3 2015 | 2015-09-30 | $378.0M | −$72.0M | −16.00% |
| Q2 2015 | 2015-06-30 | $429.0M | $232.0M | +117.77% |
| Q1 2015 | 2015-03-31 | $406.0M | $275.0M | +209.92% |
| Q4 2014 | 2014-12-31 | $468.0M | $38.0M | +8.84% |
| Q3 2014 | 2014-09-30 | $450.0M | $300.0M | +200.00% |
| Q2 2014 | 2014-06-30 | $197.0M | −$93.0M | −32.07% |
| Q1 2014 | 2014-03-31 | $131.0M | −$255.0M | −66.06% |
| Q4 2013 | 2013-12-31 | $430.0M | $60.0M | +16.22% |
| Q3 2013 | 2013-09-30 | $150.0M | −$300.0M | −66.67% |
| Q2 2013 | 2013-06-30 | $290.0M | −$155.0M | −34.83% |
| Q1 2013 | 2013-03-31 | $386.0M | −$90.0M | −18.91% |
| Q4 2012 | 2012-12-31 | $370.0M | −$48.0M | −11.48% |
| Q3 2012 | 2012-09-30 | $450.0M | $6.0M | +1.35% |
| Q2 2012 | 2012-06-30 | $445.0M | $44.0M | +10.97% |
| Q1 2012 | 2012-03-31 | $476.0M | $53.0M | +12.53% |
| Q4 2011 | 2011-12-31 | $418.0M | $32.5M | +8.43% |
| Q3 2011 | 2011-09-30 | $444.0M | −$27.0M | −5.73% |
| Q2 2011 | 2011-06-30 | $401.0M | −$47.1M | −10.51% |
| Q1 2011 | 2011-03-31 | $423.0M | −$23.4M | −5.24% |
| Q4 2010 | 2010-12-31 | $385.5M | −$128.1M | −24.94% |
| Q3 2010 | 2010-09-30 | $471.0M | $159.6M | +51.25% |
| Q2 2010 | 2010-06-30 | $448.1M | $58.3M | +14.96% |
| Q1 2010 | 2010-03-31 | $446.4M | $67.2M | +17.72% |
| Q4 2009 | 2009-12-31 | $513.6M | — | — |
| Q3 2009 | 2009-09-30 | $311.4M | −$52.7M | −14.47% |
| Q2 2009 | 2009-06-30 | $389.8M | −$11.1M | −2.77% |
| Q1 2009 | 2009-03-31 | $379.2M | — | — |
| Q3 2008 | 2008-09-30 | $364.1M | — | — |
| Q2 2008 | 2008-06-30 | $400.9M | — | — |
Stryker operating income trends
Over the last five fiscal years, Stryker's operating income increased from $2.22B to $4.89B, a change of $2.67B. The latest reported quarter, Q2 2026, shows $1.66B.
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Stryker source filings ↗Community posts
Stryker completes ZuriMED acquisition to broaden its shoulder-repair offering
Stryker ($SYK) completed its acquisition of privately held ZuriMED, adding FiberLocker technology to its sports medicine business. The commercialized product is used to augment rotator cuff repair and is designed to increase the mechanical ...